At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 372 enrolled
Drug / intervention
Deferiprone +1 moredrug
Likely dose
Deferiprone 15 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Conservative Iron Chelation as a Disease-modifying Strategy in Parkinson's Disease. European Multicentre, Parallel-group, Placebo-controlled, Randomized Clinical Trial of Deferiprone"
In Brief
A Phase 2 clinical trial evaluating Deferiprone and Placebo for Parkinson Disease. Completed, enrolled 372 participants across 25 sites in 8 countries.
Detailed Summary
This study evaluates the effect of iron chelation as a therapeutic strategy to slow the progression of Parkinson's disease. Half of participants will receive the deferiprone to 15 mg / kg twice daily morning and evening (30mg / kg per day), while the other half will receive a placebo. The treatment lasts nine months.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsParkinson Disease
CountriesAustria, Czechia, France, Germany, Netherlands, Portugal, Spain, United Kingdom
CollaboratorsEuropean Commission, ApoPharma
Timeline
Phase 2CompletedFinished
20162017201820192020202120222023202420252026
First PostedJan 2016
Enrollment StartFeb 2016
Primary CompletionSep 2020
TodayJul 2026
First PostedJan 14, 2016
Enrollment StartFeb 9, 2016
Primary CompletionSep 22, 2020
TodayJul 2, 2026
Enrollment to primary: 4.6 yearsPosted 10.5 years ago
Interventions
Deferipronedrug
15 mg / kg twice daily morning and evening (30mg / kg per day).The treatment lasts nine months.
Placebodrug
the placebo twice daily morning and evening. The treatment lasts nine months